Elanco Animal Health Incorporated $ELAN Shares Sold by Hedges Asset Management LLC

Key Points

• Hedges Asset Management LLC has reduced its stake in Elanco Animal Health by 33.8%, holding 76,500 shares valued at approximately $1.09 million after selling 39,000 shares in the second quarter.
• Elanco reported $0.26 earnings per share (EPS) for the last quarter, exceeding analysts' expectations of $0.20, with revenues of $1.24 billion.
• Despite recent performance, analysts have a consensus rating of "Moderate Buy" for Elanco, with price targets ranging from $17.00 to $19.00.

Hedges Asset Management LLC trimmed its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 33.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 76,500 shares of the company's stock after selling 39,000 shares during the period. Hedges Asset Management LLC's holdings in Elanco Animal Health were worth $1,092,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Yousif Capital Management LLC purchased a new position in shares of Elanco Animal Health during the 1st quarter worth approximately $119,000. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Elanco Animal Health during the 1st quarter worth approximately $111,000. Comerica Bank boosted its position in Elanco Animal Health by 46.4% during the first quarter. Comerica Bank now owns 49,680 shares of the company's stock worth $522,000 after acquiring an additional 15,754 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Elanco Animal Health during the first quarter worth approximately $891,000. Finally, GAMMA Investing LLC boosted its position in Elanco Animal Health by 1,743.8% during the first quarter. GAMMA Investing LLC now owns 12,390 shares of the company's stock worth $130,000 after acquiring an additional 11,718 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Up 0.2%

Shares of ELAN traded up $0.05 during midday trading on Friday, hitting $19.15. The company had a trading volume of 2,031,889 shares, compared to its average volume of 5,985,888. The company's 50 day moving average price is $16.68 and its 200 day moving average price is $13.39. The stock has a market cap of $9.51 billion, a price-to-earnings ratio of 22.25, a PEG ratio of 3.42 and a beta of 1.62. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $19.26. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.06. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company's revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Wall Street Analysts Forecast Growth

ELAN has been the topic of a number of analyst reports. Piper Sandler raised their target price on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, August 11th. William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Zacks Research lowered shares of Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 20th. UBS Group lifted their price target on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a report on Friday, August 8th. Finally, Leerink Partnrs upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 17th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Elanco Animal Health has an average rating of "Moderate Buy" and a consensus target price of $17.33.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.